Lorlatinib

Nuvalent plans to discuss new data with the FDA at a pre-new drug application meeting. \n Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.The ALKOVE-1 trial enrolled patients with advanced ALK-positive non-small cell lung cancer (NSCLC). These patients currently start on Roche’s Alecensa, switch to Pfizer’s Lorbrena when they progress and have few options for third-line treatment. Nuvalent has designed the tyrosine kinase inhibitor (TKI) neladalkib to address the resistance and safety problems of existing TKIs and to work across any line of therapy.Nuvalent reported a 31% response rate among 253 patients with advanced ALK-positive NSCLC who had previously received any prior ALK TKI. In the study\'s primary analysis population, patients had received a median of three prior lines of therapy, with 51% having previously received chemotherapy.The study was yet to reach the median duration of response (DOR) after 11.3 months of follow-up. After six months, 76% of responses were ongoing. The figure fell to 64% after 12 months and 53% after 18 months. Almost 80% of patients had received at least two ALK TKIs and 91% of participants had taken Lorbrena. The lack of effective drugs in the third-line population means there is no relevant cross-trial benchmark. Nuvalent reported a 49% response rate and 14.4-month median DOR in patients with ALK mutations and prior Lorbrena use in the phase 1 part of the trial. Nuvalent also shared data from 63 patients who hadn’t received Lorbrena. The results will shape the biotech’s attempts to replace Pfizer’s drug as the preferred second-line treatment. The response rate was 46% and the trial was yet to reach the median DOR. After six months, 89% of responses were ongoing. The figure fell to 80% after 12 months and 60% after 18 months. Guggenheim Securities analysts said in a note to investors last month that Lorbrena won approval for post-Alecensa use based on a response rate of around 40% and DOR of about seven months. Nuvalent executives told the analysts they were focused more on DOR than response rate, given the potential for the patient mix to influence the latter endpoint.“Management’s thesis was that neladalkib should drive more prolonged durability compared to [Lorbrena] on cross-trial comparison. Their goal isn’t to be marginally better, but meaningfully better so that it is a black-and-white comparison,” the analysts said.Nuvalent’s plan for wresting market share from Pfizer relies on neladalkib being more durable and less toxic than Lorbrena. The biotech said increases in two liver enzymes, which were seen in 44% and 47% of patients, were the most frequent treatment-emergent adverse events (TEAEs). At the phase 2 dose, TEAEs caused dose reductions in 17% of patients and treatment discontinuation in 5% of participants.  Nuvalent plans to discuss the data with the FDA at a pre-new drug application meeting. While Nuvalent is initially targeting the TKI pretreated, ALK-positive NSCLC population, the biotech is running a phase 3 trial to establish neladalkib in TKI-naïve patients. The phase 3 trial is pitting neladalkib against Alecensa.The biotech shared data from an exploratory cohort of 44 TKI-naïve patients who were enrolled in the phase 1/2 trial. In this group, Nuvalent reported an 86% response rate and a 9% complete response rate. Two of the 38 responders had progressed as of the data cutoff. 

In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectively In the subset of 63 TKI pre-treated patients who were lorlatinib-naïve, ORR by BICR was 46% (95% CI: 33, 59), with initial estimated durability of response of 80% and 60% at the 12- and 18-month landmarks, respectively Neladalkib demonstrated intracranial responses, ability to address key drivers of disease progression, and a generally well-tolerated safety profile with low rates of dose discontinuation (5%) and dose reduction (17%) due to TEAEs, consistent with its ALK-selective, TRK-sparing design Company plans to discuss pivotal data for the TKI pre-treated ALK-positive NSCLC population with the FDA at a pre-NDA meeting; detailed study results are planned for presentation at a future medical meeting Company to host a conference call today, November 17th at 8:00am ET CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 Phase 1/2 clinical trial. Additionally, the company shared the first report of preliminary data from the Phase 2 exploratory cohort for TKI-naïve patients with advanced ALK-positive NSCLC from the ALKOVE-1 study. "Today's announcement adds to the growing body of research that is transforming potential outcomes for ALK-positive lung cancer and offering new hope to patients," said Kirk Smith, patient and President of the Board of ALK Positive Inc. "We encourage the continued innovation and development of new therapeutic options for patients, with the hope that one day, advanced ALK-positive NSCLC could be managed as a chronic condition more often than as a life-threatening disease." "In treating ALK-positive lung cancer, our goal is not only to help patients live longer, but also to help them live well with their disease," said Alice T. Shaw, M.D., Ph.D., a thoracic oncologist at Dana-Farber Cancer Institute and ALKOVE-1 trial investigator. "These encouraging topline data suggest that neladalkib may represent a new and differentiated treatment option for ALK positive lung cancer, offering durable clinical benefit while potentially reducing the risk of side effects that can affect quality of life." "We are deeply grateful to the patients, caregivers and investigators who have made this milestone possible for our neladalkib program. I continue to be inspired by the unwavering dedication of the Nuvalent team to making a difference for patients, and humbled by the courage and conviction of the over 1,000 patients that have already chosen to receive neladalkib through either our ALKOVE-1 trial or our global Expanded Access Program," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "Our focus remains on delivering our precisely targeted therapies to patients as quickly as possible, and we look forward to discussing these pivotal data with the FDA and aligning on a potential registration path for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC." Summary of Topline Pivotal Data Neladalkib is being evaluated in ALKOVE-1, a first-in-human Phase 1/2 clinical trial for patients with advanced ALK-positive NSCLC and other solid tumors. The recommended Phase 2 dose (RP2D) for neladalkib of 150 mg once daily (QD) was determined during the Phase 1 dose-escalation portion of the trial. The global, single-arm, multi-cohort, open-label Phase 2 portion is designed to evaluate neladalkib at the RP2D with registrational intent for TKI pre-treated patients with advanced ALK-positive NSCLC. Global enrollment in ALKOVE-1 remains ongoing for adult and adolescent patients with ALK-positive solid tumors other than NSCLC, and for adolescent patients with ALK-positive NSCLC. In this topline pivotal dataset for the TKI pre-treated ALK-positive NSCLC population, data are pooled across Phase 1 and 2 and reported for the primary objective of objective response rate (ORR, RECIST 1.1) by blinded independent central review (BICR). Key secondary objectives include duration of response (DOR), intracranial ORR (IC-ORR), and safety. As of the data cut-off date of August 29, 2025, 781 patients with ALK-positive solid tumors had received neladalkib at any starting dose across the Phase 1 and Phase 2 portions of the ALKOVE-1 clinical trial. Of these, 656 patients with advanced ALK-positive NSCLC were treated with neladalkib at the RP2D. Efficacy Analysis in TKI Pre-treated Advanced ALK-positive NSCLC The pivotal primary analysis population consisted of 253 TKI pre-treated patients with advanced ALK-positive NSCLC with measurable disease by BICR who received neladalkib at the RP2D by September 30, 2024, with DOR follow-up of at least 6 months available for nearly all responders. The pivotal primary analysis population was distinct from the ALK TKI pre-treated populations that have been reported for the currently available ALK TKIs: Patients received a median of 3 prior lines of therapy (range, 1 – 11) and 51% had received prior chemotherapy. 78% of patients had received 2 or more prior ALK TKIs ± prior chemotherapy, of which 91% had received prior lorlatinib. No approved therapies have demonstrated activity after lorlatinib. 19% of patients had a secondary ALK G1202R resistance mutation, and 17% had a compound ALK resistance mutation, which are key drivers of disease progression. 40% of patients had active CNS disease by BICR at baseline. Of the overall TKI pre-treated population, 25% (63/253) of patients were lorlatinib-naïve. Within this subpopulation: 25% received prior chemotherapy. 100% had received ≥ 1 prior 2G ALK TKI ± prior chemotherapy, of which 70% received prior alectinib only. No patients received crizotinib as their only ALK TKI. 19% of patients had a secondary ALK G1202R mutation. 35% had active CNS disease by BICR at baseline. Activity was observed across subsets of TKI pre-treated patients, and durability of response was assessed as the probability of patients remaining in response for at least 6, 12, and 18 months by Kaplan-Meier estimate (Table 1). Preliminary Data from Exploratory Cohort for TKI-Naïve Patients with Advanced ALK-positive NSCLC Encouraging preliminary data were available for 44 TKI-naïve patients with advanced ALK-positive NSCLC and measurable disease by BICR. These patients were treated with neladalkib at RP2D in an exploratory cohort of ALKOVE-1, with data cut-off of August 29, 2025. Patients may have received up to one prior line of chemotherapy. The preliminary ORR was 86% (38/44; 2 uPRs) and a CR rate of 9% (4/44; 1 uCR with prior confirmed PR) was observed. DOR ranged from 1.7+ to 14.8+ months with DOR ≥ 6 and 12 months of 91% (95% CI: 70, 98) and only two progression events among responders. In 9 patients with measurable intracranial lesions, the IC-ORR was 78% (7/9) and the intracranial CR rate was 44% (4/9; 1 IC-uCR with prior confirmed IC-PR). The IC-DOR ranged from 3.1+ to 7.0+ months with no CNS progression among responders. Global enrollment of TKI-naïve patients is ongoing in ALKAZAR, Nuvalent's Phase 3 randomized controlled trial of neladalkib versus alectinib. Safety Analyses in Advanced ALK-positive NSCLC Neladalkib demonstrated a generally well-tolerated safety profile consistent with its ALK-selective, TRK-sparing design. In the 656 patients with advanced ALK-positive NSCLC treated at RP2D as of the data cut-off date, the median duration of exposure was 6.0 months (range, 0.1, 28.4). The most frequent treatment-emergent adverse events (TEAEs) occurring in ≥ 15% of patients were alanine aminotransferase increased (47%), aspartate aminotransferase increased (44%), constipation (28%), dysgeusia (23%), peripheral edema (18%), cough and nausea (16% each). The most common TEAE of transaminase elevations were generally observed to be asymptomatic lab abnormalities that were low-grade, transient, and reversible with dose interruptions or reductions. Preliminary data suggest increased incidence in less heavily pre-treated patients. Enhanced monitoring for transaminase elevations and prompt dose interventions have been implemented in the protocol for the ALKAZAR Phase 3 randomized, controlled trial. Across the 656 patients treated in ALKOVE-1 at RP2D, dose reductions due to TEAEs occurred in 17% of patients and 5% of patients discontinued treatment due to TEAEs. The company plans to discuss the topline pivotal data for TKI pre-treated ALK-positive NSCLC with the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting. Additionally, Nuvalent plans to present detailed study results at a future medical meeting. Webcast and Conference Call Information A conference call with management will be held today at 8:00 am ET. To access the call, please dial +1 (800) 836-8184 (domestic) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined to the Nuvalent call. Accompanying slides and a live video webcast will be available in the Investors section of the Nuvalent website at . A replay and accompanying slides will be archived on the Nuvalent website for 30 days. About Neladalkib Neladalkib is an investigational brain-penetrant ALK-selective inhibitor created with the aim to overcome limitations observed with currently available ALK inhibitors. Neladalkib is designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with single or compound treatment-emergent ALK mutations such as G1202R. In addition, neladalkib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with dual TRK/ALK inhibitors and to drive deep, durable responses for patients across all lines of therapy. Neladalkib has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with 2 or more ALK tyrosine kinase inhibitors and orphan drug designation for ALK-positive NSCLC. About the ALKOVE-1 Phase 1/2 and ALKAZAR Phase 3 Clinical Trials The ALKOVE-1 trial (NCT05384626) is a first-in-human Phase 1/2 clinical trial for patients with advanced ALK-positive NSCLC and other solid tumors. The completed Phase 1 portion enrolled ALK-positive NSCLC patients who previously received at least one ALK TKI, or patients with other ALK-positive solid tumors who had been previously treated or for whom no satisfactory standard of care exists. The Phase 1 portion of the trial was designed to evaluate the overall safety and tolerability of neladalkib, with additional objectives including determination of the recommended Phase 2 dose (RP2D), characterization of the pharmacokinetic profile, and evaluation of preliminary anti-tumor activity. The global, single arm, open label Phase 2 portion is designed with registrational intent for TKI pre-treated patients with advanced ALK-positive NSCLC. Global enrollment in ALKOVE-1 remains ongoing for adult and adolescent patients with ALK-positive solid tumors outside of NSCLC, and adolescent patients with ALK-positive NSCLC. The ALKAZAR trial (NCT06765109) is a global, randomized, controlled trial designed to enroll approximately 450 patients with TKI-naïve ALK-positive NSCLC. Patients are randomized 1:1 to receive neladalkib or ALECENSA® (alectinib). The primary endpoint is progression free survival (PFS) based on Blinded Independent Central Review (BICR). Secondary endpoints include PFS based on investigator's assessment, and BICR assessment of objective response rate (ORR), intracranial objective response rate (IC-ORR), overall survival (OS), and safety. About Nuvalent Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the expected timing of data announcements; the clinical development programs for our investigational product candidates, including neladalkib; the potential clinical effects of our investigational product candidates, including neladalkib; the design and enrollment of Nuvalent's clinical trials, including for the ALKOVE-1 and ALKAZAR trials their intended pivotal registration-directed design; the potential of Nuvalent's pipeline programs, including neladalkib, zidesamtinib and NVL-330; the implications of data readouts and presentations; timing and content of FDA submissions and interactions; Nuvalent's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: risks that Nuvalent may not fully enroll its clinical trials or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that preliminary results of clinical trials may not be predictive of future results from the same or other trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from our clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib and neladalkib; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ALKOVE-1 and ALKAZAR trials; the timing and outcome of Nuvalent's planned interactions with regulatory authorities and the ability of Nuvalent to interact with such officials as a result of government shutdowns or other political circumstances; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements. SOURCE Nuvalent, Inc. 21% more press release views with Request a Demo